ACP-196 in combination with pembrolizumab

DRUG2 trials

Sponsors

Acerta Pharma BV

Conditions

Metastatic Pancreatic CancerMetastatic Urothelial Carcinoma

Phase 2

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

CompletedNCT02351739

Acerta Pharma BVMetastatic Urothelial Carcinoma

Start: 2015-04-30End: 2018-04-30Updated: 2019-09-10

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

CompletedNCT02362048

Acerta Pharma BVMetastatic Pancreatic Cancer

Start: 2015-05-31End: 2017-03-31Updated: 2019-10-01

Related Papers

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Journal for ImmunoTherapy of Cancer2020-02-0187 citations

Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).

Journal of Clinical Oncology2019-03-01

Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2018-05-20

Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).

Journal of Clinical Oncology2018-05-20

A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).

Journal of Clinical Oncology2016-05-2018 citations